Alexander M. Castellino

Melanoma patients showed intracranial responses when they received both a BRAF and MEK inhibitor.

Intracranial and extracranial responses were provided with combination immunotherapy with nivolumab and ipilimumab, for patients with melanoma and brain metastases.

Talimogene laherparepvec along with ipilimumab improves the overall response rate over just ipilimumab among patients with unresected, advanced melanoma.